Chardan Capital Analysts Cut Earnings Estimates for Femasys Inc. (NASDAQ:FEMY)

Femasys Inc. (NASDAQ:FEMY) – Analysts at Chardan Capital cut their FY2024 earnings per share (EPS) estimates for Femasys in a research note issued on Wednesday, August 14th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($0.79) per share for the year, down from their prior forecast of ($0.75). Chardan Capital currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.72) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.56) EPS.

Femasys (NASDAQ:FEMY) last posted its earnings results on Thursday, August 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.03). The company had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.50 million. Femasys had a negative return on equity of 104.06% and a negative net margin of 1,420.59%.

Separately, HC Wainwright reduced their price target on shares of Femasys from $13.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 9th.

Femasys Stock Down 5.7 %

Shares of NASDAQ FEMY opened at $1.00 on Monday. Femasys has a 52-week low of $0.25 and a 52-week high of $4.75. The company has a debt-to-equity ratio of 0.29, a quick ratio of 8.02 and a current ratio of 8.43. The stock has a market cap of $22.22 million, a P/E ratio of -1.19 and a beta of -2.81. The firm has a 50 day moving average price of $1.09 and a 200 day moving average price of $1.31.

Institutional Investors Weigh In On Femasys

An institutional investor recently raised its position in Femasys stock. Clear Creek Financial Management LLC increased its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 30.6% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 309,274 shares of the company’s stock after purchasing an additional 72,505 shares during the quarter. Clear Creek Financial Management LLC owned 1.40% of Femasys worth $479,000 as of its most recent filing with the SEC. 65.27% of the stock is currently owned by hedge funds and other institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.